Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

BACKGROUND: Data suggest that immunomodulation induced by DNA hypomethylating agents can sensitize tumors to immune checkpoint inhibitors. We conducted a phase 1 dose-escalation trial (NCT02998567) of guadecitabine and pembrolizumab in patients with advanced solid tumors. We hypothesized that guadec...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadatos-Pastos, Dionysis, Yuan, Wei, Pal, Abhijit, Crespo, Mateus, Ferreira, Ana, Gurel, Bora, Prout, Toby, Ameratunga, Malaka, Chénard-Poirier, Maxime, Curcean, Andra, Bertan, Claudia, Baker, Chloe, Miranda, Susana, Masrour, Nahal, Chen, Wentin, Pereira, Rita, Figueiredo, Ines, Morilla, Ricardo, Jenkins, Ben, Zachariou, Anna, Riisnaes, Ruth, Parmar, Mona, Turner, Alison, Carreira, Suzanne, Yap, Christina, Brown, Robert, Tunariu, Nina, Banerji, Udai, Lopez, Juanita, de Bono, Johann, Minchom, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240883/
https://www.ncbi.nlm.nih.gov/pubmed/35717027
http://dx.doi.org/10.1136/jitc-2022-004495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240883/
https://www.ncbi.nlm.nih.gov/pubmed/35717027
http://dx.doi.org/10.1136/jitc-2022-004495

Ejemplares similares